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P U B L I S H E D B Y E L S E V I E R I N C .LettersBotulinum Toxin Injection
in Epicardial Fat Pads
Can Prevent Recurrences
of Atrial Fibrillation After
Cardiac Surgery
Results of a Randomized Pilot StudyAtrial ﬁbrillation (AF) is a common complication of
cardiac surgery. The incidence of post-operative AF is
10% to 50%, usually occurring 2 to 5 days after sur-
gery (1). In light of the increased short- and long-term
risks of patients who develop post-operative AF, it is
of particular importance to consider ways to reduce
its burden.
Animal models suggest that botulinum toxin in-
jection into the epicardial fat pads suppresses AF
inducibility (2). The aim of this prospective, ran-
domized double-blind pilot study (Botulinum Toxin
Injection in Epicardial Fat Pads To Treat Atrial
Fibrillation After Cardiac Surgery; NCT01842529) was
to compare the efﬁcacy and safety of botulinum toxin
injection into epicardial fat pads for the prevention of
recurrences of atrial tachyarrhythmia in the post-
operative period in patients with paroxysmal AF
(PAF) undergoing coronary artery bypass graft (CABG)
surgery.
This parallel-group, 2-center study compared
treatment with botulinum toxin to 0.9% normal saline
(placebo). The inclusion criteria were pre-operative
history of PAF and an indication for CABG, according
to the American College of Cardiology/American Heart
Association guidelines.
The exclusion criteria were previous heart surgery
or AF ablation procedure; emergency CABG; unstable
angina or heart failure; persistent AF or AF at the time
of screening; planned Maze procedure or pulmonary
vein isolation; use of class I or III antiarrhythmic drugs
within 5 elimination half-lives of the drug (or with-
in 2 months for amiodarone); need for concomitant
valve surgery; and unwillingness to participate.
Patients were randomized to a botulinum toxin
(Xeomin, incobotulinumtoxin A, Merz Pharma GmbH
& Co KGaA, Frankfurt am Main, Germany) (n ¼ 30) or0.9% normal saline (control; n ¼ 30) injection into
epicardial fat pads. Patients were followed for 30 days
to assess maintenance of sinus rhythm.
Our hypothesis was that a botulinum toxin injec-
tion into epicardial fat pads could prevent recurrences
of atrial tachyarrhythmia in the post-operative period
in patients undergoing CABG surgery. The primary
endpoint was recurrence of >30 s of any atrial tachy-
arrhythmia, including AF and atrial ﬂutter/tachy-
cardia, after a CABG procedure with no antiarrhythmic
drug. The secondary endpoints included time in-
tervals from end of surgery to extubation and dis-
charge from the intensive care unit (ICU), creatine
kinase-myocardial band (CK-MB) levels, post-CABG
length of stay, congestive heart failure, sustained
ventricular arrhythmias, myocardial infarction, in-
fection, renal failure, respiratory failure, stroke or
transient ischemic attack, rehospitalization, ICU
readmission, and death within 30 days.
All patients underwent conventional CABG. After
surgery, botulinum toxin (50 U/ml at each fat pad) or
0.9% normal saline (1 ml at each fat pad; placebo
group) was injected into the entire visible area of the
4 major epicardial fat pads. Technically, injections
were performed using a conventional insulin syringe
(1 ml) in 2 stages. The ﬁrst stage was a needle punc-
ture at 45 relative to the surface of the fat pad at a
depth of 2 mm; the second had an additional 2-mm
advancement of the needle, parallel to the surface
of the pad. After needle placement, adipose tissue
inﬁltration was performed by injection of solution at
volumes 0.2 to 0.3 ml per puncture. Inﬁltration zone
had a distinctive whitish color and clear boundary,
and was 5 to 6 mm in diameter. To cover the entire
surface of the fat pad, it was necessary to create 3 to
5 inﬁltration zones.
Weekly electrocardiograms (ECGs) and 24-h Holter
monitor recordings were performed at 7, 14, 21, and
30 days. Patients were instructed to report symp-
toms suggestive of AF and to undergo prompt ECG
recording.
In the study, 60 patients were enrolled (30 in each
arm). There were no baseline differences between
groups. Most patients were male (80%), with an
average age of 62.3 years. There were no differences
in the number of grafts placed (venous or arterial),
duration of aorta cross-clamping, or number of
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FIGURE 1 Kaplan-Meier Curves
Shown is time to atrial ﬁbrillation (AF) after coronary artery
bypass grafting (CABG).
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629off-pump CABG surgeries performed between groups
(all p > 0.05). There were no signiﬁcant differences in
the median time to extubation, or intervals from the
end of surgery to eligibility for and to actual discharge
from the ICU (all p > 0.05). There were no signiﬁcant
differences in CK-MB levels in the post-operative
period.
Overall, the incidence of post-operative AF was
18% (11 of 60 patients). Post-operative AF occurred
in 2 (7%) of 30 patients in the botulinum toxin group
and in 9 (30%) of 30 patients in the placebo group
(log-rank test p ¼ 0.024) (Fig. 1). The AF burden on
24-h Holter also favored the botulinum toxin group,
0.3% versus 2.5% (p ¼ 0.08). The mean duration of
AF episodes were 0.94  1.1 h in the botulinum
toxin group and 2.83  6.6 h in the placebo group
(p ¼ 0.17).
There was no signiﬁcant difference in the post-
operative hospital length of stay between groups
(p ¼ 0.12), with a median (25th to 75th percentile)
length of stay of 6 (5 to 8) days in the botulinum toxin
group versus 6 (4 to 8) days in the placebo group.
Other post-operative complications, including death,
were similar between groups (all p > 0.05).
The main ﬁndings of this study were botulinum
toxin injection into the epicardial fat pads prevented
recurrences of atrial tachyarrhythmia in the post-
operative period in patients with prior PAF undergo-
ing CABG; and the botulinum toxin injection did not
alter timing of discharge from the ICU, nor enhance
post-operative hospital length of stay or any other
post-operative complication.Because in the vast majority of these patients,
post-operative AF is a transient phenomenon, per-
manent ganglionated plexi (GP) destruction should
not be the method of choice. Temporary autonomic
blockade without permanent destruction of the GP
during the post-operative period would be expected
to produce favorable results in the short term, coin-
ciding with post-operative risk of AF. Our study
strongly supports this hypothesis by utilizing a novel
therapy.
This is a “ﬁrst-in-man” study of botulinum toxin
injection into the epicardial fat pads, resulting in
the enrollment of a limited number of patients.
Although the study was randomized, double-blind,
and prospective, the results will require validation
in larger trials. The major limitation of the study is
the failure to clarify the mechanisms underlying
the transient nature of post-operative AF and the
ability of GP inactivation by botulinum toxin to
attenuate post-operative AF. Perhaps this study
will initiate additional studies utilizing this new
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